[Experience in treating peripheral T-cell lymphomas by a new program].
To treat patients with an accurately verified peripheral T-cellular lymphoma presenting with a high degree malignancy, there has been used a new aggressive chemotherapeutic protocol "Bu". It is more effective than the well known protocol CHOP. 83% patients achieved complete remission as well as long-term survival. Immunophenotyping of cells of malignant lymphomas had been done before choosing the relevant chemotherapeutic treatment policy.
Butenko
A K
AK
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D012189:Retrospective Studies; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
Opyt lecheniia perifericheskikh T-kletochnykh limfom po novoĭ programme.